[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity
Stan V. Smith, a director of MAIA Biotechnology, Inc. (MAIA), purchased 19,230 shares of common stock on 10/01/2025 at a price of $1.30 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. The transaction increased beneficial ownership to 1,324,289 shares, held indirectly through The Stan V. Smith Trust Dated 1993. In the same transaction Mr. Smith acquired 19,230 warrants (treated as options) with a $1.57 exercise price; those options become exercisable six months after issuance and expire three years after issuance (exercise window: 04/01/2026 through 10/01/2028). The Form 4 was signed on 10/02/2025.
Stan V. Smith, un direttore di MAIA Biotechnology, Inc. (MAIA), ha acquistato 19,230 azioni ordinarie il 01/10/2025 al prezzo di $1,30 per azione ai sensi di un Securities Purchase Agreement e del 2021 Equity Incentive Plan della società. La transazione ha aumentato la proprietà beneficiaria a 1.324.289 azioni, detenute indirettamente tramite The Stan V. Smith Trust Dated 1993. Nella stessa operazione, il signor Smith ha acquisito 19.230 warrant (trattati come opzioni) con prezzo di esercizio di $1,57; tali opzioni diventano esercitabili sei mesi dopo l'emissione e scadono tre anni dopo l'emissione (finestra di esercizio: 04/01/2026 fino a 10/01/2028). Il Form 4 è stato firmato il 02/10/2025.
Stan V. Smith, un director de MAIA Biotechnology, Inc. (MAIA), compró 19,230 acciones comunes en 10/01/2025 a un precio de $1.30 por acción conforme a un Securities Purchase Agreement y al Plan de Incentivo de Capital 2021 de la empresa. La operación incrementó la titularidad a favor de 1,324,289 acciones, mantenidas indirectamente a través de The Stan V. Smith Trust Dated 1993. En la misma transacción, el señor Smith adquirió 19,230 warrants (tratados como opciones) con un precio de ejercicio de $1.57; esas opciones son ejercitables seis meses después de la emisión y expiran tres años después de la emisión (ventana de ejercicio: 04/01/2026 a 10/01/2028). El Form 4 fue firmado el 02/10/2025.
Stan V. Smith은 MAIA Biotechnology, Inc. (MAIA)의 이사로, MAIA Biotechnology, Inc. (MAIA)의 19,230 주의 보통주를 2025년 10월 1일에 주당 $1.30의 가격으로 주식매입계약 및 회사의 2021 Equity Incentive Plan에 따라 매수했습니다. 이 거래로 실질 소유 지분은 1,324,289 주로 증가했으며, The Stan V. Smith Trust Dated 1993를 통해 간접 보유합니다. 같은 거래에서 Smith 씨는 19,230 개의 워런트(옵션으로 취급)를 $1.57의 행사가격으로 취득했습니다. 이 옵션은 발행 후 6개월 후 행사 가능하며 발행 후 3년 동안 만료됩니다(행사 창: 2026-04-01부터 2028-10-01까지). Form 4는 2025년 10월 2일에 서명되었습니다.
Stan V. Smith, un directeur de MAIA Biotechnology, Inc. (MAIA), a acheté 19 230 actions ordinaires le 01/10/2025 au prix de 1,30 $ par action dans le cadre d'un Securities Purchase Agreement et du Plan d'intéressement en actions 2021 de la société. La transaction a augmenté la détention bénéficiaire à 1 324 289 actions, détenues indirectement via The Stan V. Smith Trust Dated 1993. Dans la même transaction, M. Smith a acquis 19 230 warrants (considérés comme des options) avec un prix d'exercice de 1,57 $; ces options deviennent exerçables six mois après l'émission et expirent trois ans après l'émission (fenêtre d'exercice : 01/04/2026 à 01/10/2028). Le Form 4 a été signé le 02/10/2025.
Stan V. Smith, ein Direktor von MAIA Biotechnology, Inc. (MAIA), kaufte 19.230 Stammaktien am 01.10.2025 zu einem Preis von $1,30 pro Aktie im Rahmen eines Wertpapierkaufvertrags und des unternehmensweiten 2021 Equity Incentive Plan. Die Transaktion erhöhte die wirtschaftliche Eigentümerschaft auf 1.324.289 Aktien, indirekt gehalten über The Stan V. Smith Trust Dated 1993. Im gleichen Geschäft erwarb Herr Smith 19.230 Warrants (als Optionen behandelt) mit einem Ausübungspreis von $1,57; diese Optionen sind sechs Monate nach der Emission ausübbar und verfallen drei Jahre nach der Emission (Ausübungsfenster: 01.04.2026 bis 01.10.2028). Das Form 4 wurde am 02.10.2025 unterzeichnet.
ستان ف. سميث، مدير في MAIA Biotechnology, Inc. (MAIA)، اشترى 19,230 سهماً عادياً في 01/10/2025 بسعر $1.30 للسهم وفقاً لاتفاقية شراء الأوراق المالية وخطة التحفيز بالأسهم 2021 Equity Incentive Plan للشركة. زادت الصفقة الملكية إلى 1,324,289 سهم، مملوكة بشكل غير مباشر من خلال The Stan V. Smith Trust Dated 1993. في نفس الصفقة، حصل السيد سميث على 19,230 Warrants (معالجة كخيارات) بسعر ممارسة قدره $1.57؛ تصبح هذه الخيارات قابلة للتنفيذ بعد ستة أشهر من الإصدار وتنتهي صلاحيتها بعد ثلاث سنوات من الإصدار (نافذة التمرين: 04/01/2026 حتى 10/01/2028). تم توقيع النموذج 4 في 02/10/2025.
Stan V. Smith，是 MAIA Biotechnology, Inc. (MAIA) 的 董事，在 2025/10/01 以每股 $1.30 的价格，依据证券购买协议和公司的 2021 年股权激励计划，购买了19,230股普通股。该交易使受益所有权增至 1,324,289 股，通过 The Stan V. Smith Trust Dated 1993 间接持有。 同一笔交易中，Smith 先生还获得了 19,230 张认股权证（按作选择）行使价为 $1.57；这些期权在发行后六个月可行使，发行后三年内到期（行使窗口：2026-04-01 至 2028-10-01）。Form 4 于 2025-10-02 签署。
- Insider purchase of 19,230 shares demonstrates director buying company stock
- Beneficial ownership increased to 1,324,289 shares, consolidating director's stake
- Associated warrants/options are not exercisable for six months, delaying potential conversion
- Warrants expire in three years, creating a limited exercise window
Insights
Director purchased common stock and warrants, increasing indirect holdings to 1,324,289 shares.
The filing shows a 10/01/2025 purchase of 19,230 common shares at $1.30 and acquisition of 19,230 warrants with a $1.57 exercise price under the issuer’s 2021 Equity Incentive Plan. Beneficial ownership is held indirectly via The Stan V. Smith Trust Dated 1993, and total post-transaction holdings are reported as 1,324,289 shares.
The warrants/options are subject to a six-month vesting delay (not exercisable until the six-month anniversary) and expire three years after issuance, which limits immediate liquidity from the derivative position. The transaction was reported on a standard Form 4 and signed on 10/02/2025.
Stan V. Smith, un direttore di MAIA Biotechnology, Inc. (MAIA), ha acquistato 19,230 azioni ordinarie il 01/10/2025 al prezzo di $1,30 per azione ai sensi di un Securities Purchase Agreement e del 2021 Equity Incentive Plan della società. La transazione ha aumentato la proprietà beneficiaria a 1.324.289 azioni, detenute indirettamente tramite The Stan V. Smith Trust Dated 1993. Nella stessa operazione, il signor Smith ha acquisito 19.230 warrant (trattati come opzioni) con prezzo di esercizio di $1,57; tali opzioni diventano esercitabili sei mesi dopo l'emissione e scadono tre anni dopo l'emissione (finestra di esercizio: 04/01/2026 fino a 10/01/2028). Il Form 4 è stato firmato il 02/10/2025.
Stan V. Smith, un director de MAIA Biotechnology, Inc. (MAIA), compró 19,230 acciones comunes en 10/01/2025 a un precio de $1.30 por acción conforme a un Securities Purchase Agreement y al Plan de Incentivo de Capital 2021 de la empresa. La operación incrementó la titularidad a favor de 1,324,289 acciones, mantenidas indirectamente a través de The Stan V. Smith Trust Dated 1993. En la misma transacción, el señor Smith adquirió 19,230 warrants (tratados como opciones) con un precio de ejercicio de $1.57; esas opciones son ejercitables seis meses después de la emisión y expiran tres años después de la emisión (ventana de ejercicio: 04/01/2026 a 10/01/2028). El Form 4 fue firmado el 02/10/2025.
Stan V. Smith은 MAIA Biotechnology, Inc. (MAIA)의 이사로, MAIA Biotechnology, Inc. (MAIA)의 19,230 주의 보통주를 2025년 10월 1일에 주당 $1.30의 가격으로 주식매입계약 및 회사의 2021 Equity Incentive Plan에 따라 매수했습니다. 이 거래로 실질 소유 지분은 1,324,289 주로 증가했으며, The Stan V. Smith Trust Dated 1993를 통해 간접 보유합니다. 같은 거래에서 Smith 씨는 19,230 개의 워런트(옵션으로 취급)를 $1.57의 행사가격으로 취득했습니다. 이 옵션은 발행 후 6개월 후 행사 가능하며 발행 후 3년 동안 만료됩니다(행사 창: 2026-04-01부터 2028-10-01까지). Form 4는 2025년 10월 2일에 서명되었습니다.
Stan V. Smith, un directeur de MAIA Biotechnology, Inc. (MAIA), a acheté 19 230 actions ordinaires le 01/10/2025 au prix de 1,30 $ par action dans le cadre d'un Securities Purchase Agreement et du Plan d'intéressement en actions 2021 de la société. La transaction a augmenté la détention bénéficiaire à 1 324 289 actions, détenues indirectement via The Stan V. Smith Trust Dated 1993. Dans la même transaction, M. Smith a acquis 19 230 warrants (considérés comme des options) avec un prix d'exercice de 1,57 $; ces options deviennent exerçables six mois après l'émission et expirent trois ans après l'émission (fenêtre d'exercice : 01/04/2026 à 01/10/2028). Le Form 4 a été signé le 02/10/2025.
Stan V. Smith, ein Direktor von MAIA Biotechnology, Inc. (MAIA), kaufte 19.230 Stammaktien am 01.10.2025 zu einem Preis von $1,30 pro Aktie im Rahmen eines Wertpapierkaufvertrags und des unternehmensweiten 2021 Equity Incentive Plan. Die Transaktion erhöhte die wirtschaftliche Eigentümerschaft auf 1.324.289 Aktien, indirekt gehalten über The Stan V. Smith Trust Dated 1993. Im gleichen Geschäft erwarb Herr Smith 19.230 Warrants (als Optionen behandelt) mit einem Ausübungspreis von $1,57; diese Optionen sind sechs Monate nach der Emission ausübbar und verfallen drei Jahre nach der Emission (Ausübungsfenster: 01.04.2026 bis 01.10.2028). Das Form 4 wurde am 02.10.2025 unterzeichnet.
FAQ
What did MAIA director Stan V. Smith purchase on 10/01/2025?
How many MAIA shares does Stan V. Smith beneficially own after the transaction?
Through what vehicle does Stan V. Smith hold these MAIA securities?
When can the warrants/options be exercised and when do they expire?
When was the Form 4 signed and filed?
